Grant Mcarthur

Sort by:

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Paul B Chapman, A. H. W. Hauschild, +25 authors Grant Mcarthur
The New England journal of medicine
2011

BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E… (More)

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Ramin Nazarian, Hubing Shi, +13 authors Roger S. Lo
Nature
2010

Activating B-RAF(V600E) (also known as BRAF) kinase mutations occur in ∼7% of human malignancies and ∼60% of melanomas. Early clinical experience with a novel class I RAF-selective inhibitor,… (More)

Inhibition of mutated, activated BRAF in metastatic melanoma.

Keith T. Flaherty, Igor J. Puzanov, +8 authors Paul B Chapman
The New England journal of medicine
2010

BACKGROUND The identification of somatic mutations in the gene encoding the serine-threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to test oncogene-targeted… (More)

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James M. G. Larkin, Vanna Chiarion-Sileni, +28 authors Jedd D Wolchok
The New England journal of medicine
2015

BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have… (More)

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Jessie Villanueva, A Vultur, +18 authors Meenhard Herlyn
Cancer cell
2010

BRAF is an attractive target for melanoma drug development. However, resistance to BRAF inhibitors is a significant clinical challenge. We describe a model of resistance to BRAF inhibitors developed… (More)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Gideon E. Bollag, Peter Hirth, +37 authors Keith B. Nolop
Nature
2010

B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumours are… (More)

Effi cacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George Daniel Demetri, A. van Oosterom, +12 authors Paolo Giovanni Casali
2006

www.thelancet.com Vol 368 October 14, 2006 1329 Introduction Gastrointestinal stromal tumours are a form of sarcoma and the most common mesenchymal tumour of the gastrointestinal tract,… (More)

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Jeffrey A. Sosman, Kevin B Kim, +22 authors Antoni Ribas
The New England journal of medicine
2012

BACKGROUND Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced… (More)

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

James M. G. Larkin, Paolo Antonio Ascierto, +16 authors Antoni Ribas
The New England journal of medicine
2014

BACKGROUND The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF… (More)

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial.

Danny Rischin, Richard J. Young, +8 authors Grant Mcarthur
Journal of clinical oncology : official journal…
2010

PURPOSE To determine the prognostic importance of p16 and human papillomavirus (HPV) in patients with oropharyngeal cancer treated on a phase III concurrent chemoradiotherapy trial. PATIENTS AND… (More)

Filter Results:

Publication Year

Publication Type

Co-author

Journals and Conferences